Recent Updates
Recently added Catalysts

ODT #2 with water

Phase 1

Migraine | Small molecule | Neurology |Pfizer, Inc.|Last Updated: Sep 4, 2026

Target and mechanism

ModalitySmall molecule

Also known as ODT2 Test formulation

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLED
Total Trials1
Total Enrollment36

FDA Designations

No designations recorded

Clinical trial landscape

ODT #2 with water · 1 trial · 1 indication

Phase 1 1
NCT07594769A Study to Compare the Blood Levels of Two Dosage Formulations of the Study Medicine in Healthy AdultsMigraine
COMPLETED36 Analytics
PHASE1COMPLETED
A Study to Compare the Blood Levels of Two Dosage Formulations of the Study Medicine in Healthy Adults
Migraine
NCT0759476936
Unlock trial analytics

Study Endpoints

Primary Endpoints

Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUCinf) of the test and reference formulations
Pre-dose to 72 hours
Area under the plasma concentration-time curve from time zero to time of last measurable concentration (AUClast) of the test and reference formulations
Pre-dose to 72 hours
Maximum observed plasma concentration (Cmax) of test and reference formulations
Pre-dose to 72 hours

Secondary Endpoints

Number of participants with treatment emergent adverse events (TEAEs)
From baseline up to 36 days after last dose of study intervention
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeOTHER

Treatment Arms

ArmTypeDescription
Treatment Sequence 1EXPERIMENTAL -
Treatment Sequence 2EXPERIMENTAL -

Interventions

NameTypeDescription
ODT2 Test formulationDRUGTest Formulation
ODT Reference formulationDRUGReference Formulation
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Male or female participants aged 18 years or older (or the minimum age of consent in accordance with local regulations) at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and ECGs. 2. Hav...

Countries:Belgium
Unlock Eligibility Criteria

Competitive Landscape -Migraine 29 trials

CompanyTickerTrialsLead PhaseDrugs
AbbVie, Inc.ABBV12PHASE3Atogepant
Pfizer Inc.PFE9PHASE3Rimegepant
Eli Lilly and CompanyLLY2PHASE3Galcanezumab
Amgen Inc.AMGN2PHASE3Erenumab Dose 1
Ki Health Partners. LLCRVNC1 - Daxibotulinumtonix A
Unlock Competitive Intelligence

Recent Changes (Last 90 Days)

HIGHSep 4, 2026NCT07594769Status: RECRUITING → COMPLETED
HIGHSep 4, 2026NCT07594769Status: RECRUITING → COMPLETED

Frequently asked questions about ODT #2 with water

What is ODT2 Test formulation used for?

ODT2 Test formulation is an investigational small molecule being developed for the treatment of migraine. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied in healthy adults to assess its pharmacokinetic profile.

Who makes ODT2 Test formulation?

ODT2 Test formulation is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetics in healthy volunteers.

What phase is ODT2 Test formulation in?

ODT2 Test formulation is in Phase 1 clinical development. It is an investigational drug and has not received regulatory approval. The ongoing Phase 1 trial is designed to compare blood levels of two dosage formulations of the study medicine in healthy adults.

What clinical trials is ODT2 Test formulation in?

ODT2 Test formulation is being evaluated in one active Phase 1 clinical trial, identified as NCT07594769. This study, titled 'A Study to Compare the Blood Levels of Two Dosage Formulations of the Study Medicine in Healthy Adults,' is a controlled, randomized trial enrolling 36 healthy volunteers in Belgium.

Is ODT2 Test formulation the same as any other drug?

ODT2 Test formulation is a specific dosage form being studied by Pfizer. The trial NCT07594769 compares two dosage formulations of the same study medicine, but no alternative names for the drug have been disclosed in the available information.